Pioneers targeted molecules that halt disease by selectively blocking protein synthesis within the ribosome’s exit tunnel.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Initial Therapeutics is pioneering a novel approach to disease intervention by selectively terminating protein synthesis in the exit tunnel of the ribosome. The company designs molecules that target key proteins involved in disease, aiming to stop diseases at their initial stages.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Initial Therapeutics Management Team
Investors
Apple Tree Partners
Initial Therapeutics Valuations & Financials
View real-time NPM data on Initial Therapeutics stock including daily Initial Therapeutics stock price estimates, valuation history, and historical share price information. Access Initial Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Initial Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Initial Therapeutics? Get in touch to learn more.
Similar Companies
like Initial Therapeutics
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
Pluto Biosciences
Enterprise Software
Provides a platform that analyzes and visualizes biological data to help researchers collaborate and accelerate scientific discovery.
Eightfold ai
AI & Machine Learning
Operates a Talent Intelligence Platform that provides talent acquisition and management solutions.
test.ai
Enterprise Software
Automates testing that creates and runs real-user scenarios to uncover quality issues in apps without manual scripting.
Sourcemap
Commerce & Marketplaces
Supply chain mapping and monitoring platform that enables businesses to visualize, track, and manage end-to-end supply chain operations.
Levyx
Enterprise Software
Develops software that processes large datasets in real time with high speed and efficiency to enable advanced analytics and lower infrastructure costs.
FAQ
We have answers
Initial Therapeutics stock does not trade on public stock exchanges. Initial Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Initial Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Initial Therapeutics Stock does not trade on public stock exchanges. In order to sell Initial Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Initial Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Initial Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Initial Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Initial Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Initial Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Initial Therapeutics is a private company and has not had an IPO. There is currently no Initial Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Initial Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
